Early results for a GSK gynaecological cancer drug GSK reported promising early results from a drug trial targeting ovarian and womb cancers. The treatment, named Mo Rez, reduced or eliminated tumours in more than 60% of patients in the study results highlighted. For patients and clinicians,…
Continue reading...
Continue reading...